表紙
市場調查報告書
商品編碼
1024218

NTRK融合遺傳基因陽性癌症 - KOL檢驗之流行病學調查:現在及今後的市場機會,流行病學調查,市場動態,開發平台分析,r-NPV分析

KOL Validated Epidemiological Studies of NTRK Gene Fusion Positive Cancers - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版日期: | 出版商: GervanoRA Data Services LLP | 英文 355 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供NTRK融合遺傳基因陽性癌症的相關調查,提供流行病學研究,市場規模和預測,活用KOL洞察的新加入企業價格策略,風險調整淨現值(RNPV)分析,開發管線洞察和基準概述,競爭情形,未滿足需求和機會等資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 NTRK融合遺傳基因陽性癌症的概要與流行病學調查

第4章 NTRK融合遺傳基因陽性癌症的市場銷售額:現在·預測(2020-2030)

第5章 開發平台(管線)的洞察和基準預測

第6章 NTRK融合遺傳基因陽性癌症競爭空間的交易活動

第7章 NTRK融合遺傳基因陽性癌症管線藥物的專利比較分析

第8章 風險調整淨現值(R-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH902

GervanoRA's pipeline analysis and opportunity assessment report "KOL Validated Epidemiological Studies of NTRK Gene Fusion Positive Cancers - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed NTRK Gene Fusion Positive Cancers pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in NTRK Gene Fusion Positive Cancers drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the NTRK Gene Fusion Positive Cancers area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in NTRK Gene Fusion Positive Cancers drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the NTRK Gene Fusion Positive Cancers historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current NTRK Gene Fusion Positive Cancers Market (2020) and the Forecasted NTRK Gene Fusion Positive Cancers Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of NTRK Gene Fusion Positive Cancers Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the NTRK Gene Fusion Positive Cancers Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of NTRK Gene Fusion Positive Cancers Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: NTRK GENE FUSION POSITIVE CANCERS OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: NTRK GENE FUSION POSITIVE CANCERS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF NTRK GENE FUSION POSITIVE CANCERS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF NTRK GENE FUSION POSITIVE CANCERS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: MARKET RESEARCH DATA ON APPROVED TRK INHIBITOR DRUGS (USD)
  • TABLE 03: ESTIMATED AVERAGE SELLING PRICES OF FILED AND LATE-CLINICAL STAGE TRK TARGETED PIPELINE DRUGS
  • TABLE 04: PERCEIVED VALUE OF TRK INHIBITORS PRESCRIPTION DRUG BY COMPETITIVE BENCHMARKING
  • TABLE 05: FINANCING DEALS IN TRK INHIBITOR THERAPEUTIC AREA
  • TABLE 06: LICENSING DEALS
  • TABLE 07: MERGER AND ACQUISITION DEALS
  • TABLE 08: COLLABORATION DEALS
  • TABLE 09: TRK INHIBITORS PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • TABLE 10: PRE-REGISTRATION STAGE PIPELINE DRUGS
  • TABLE 11: PHASE III PIPELINE DRUGS
  • TABLE 12: PHASE II PIPELINE DRUGS
  • TABLE 13: TRK INHIBITOR PHASE I PIPELINE MOLECULES
  • TABLE 14: TRK INHIBITOR PRE-CLINICAL PIPELINE MOLECULES
  • TABLE 15: TERMINATED TRK INHIBITORS PIPELINE MOLECULES
  • TABLE 16: PIPELINE DRUGS ALONG WITH ANTICIPATED REGION OF APPROVAL
  • TABLE 17: CLINICAL STAGE PIPELINE DRUGS WITH ORAL ROUTE OF ADMINISTRATION
  • TABLE 18: PIPELINE DRUGS WITH THEIR MOLECULAR TARGET RECEPTORS
  • TABLE 19: PIPELINE DRUGS WITH THEIR TARGETED INDICATIONS
  • TABLE 20: TRK TARGETED PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY EVENTS IN THE TRK BASED THERAPIES COMPETITIVE SPACE
  • FIGURE 02: FORECASTED ANNUAL INCREASE IN TRK INHIBITORS DRUG MARKET
  • FIGURE 03: TRK INHIBITORS TOTAL MARKET SHARE
  • FIGURE 04: COMPARISON OF TRK INHIBITORS MARKET TARGETING NTRK FUSION CANCERS & OTHER INDICATIONS
  • FIGURE 05: COMPARISON OF ESTIMATED SALES FOR THE KEY LATE CLINICAL STAGE DRUGS
  • FIGURE 06: COMPARISON OF EXPECTED PEAK SALES OF SITRAVATINIB AND REPOTRECTINIB
  • FIGURE 07: ESTIMATED MARKET SHARE OF TRK INHIBITORS TARGETING NTRK GENE FUSION POSITIVE CANCERS IN 2029
  • FIGURE 08: TRK INHIBITORS DRUG PIPELINE SCENARIO, DRUG CANDIDATES VS HSD AND COMPANY TYPE
  • FIGURE 09: SHARE OF PREVALENCE OF THREE MAJOR CANCERS WITH NTRK GENE FUSIONS - WORLDWIDE
  • FIGURE 10: SHARE OF PREVALENCE OF OTHER CANCERS WITH NTRK GENE FUSIONS - WORLDWIDE
  • FIGURE 11: NEW CASES OF NTRK GENE FUSION-POSITIVE LUNG CANCER - WORLDWIDE
  • FIGURE 12: PREVALENCE RATE PER 100000 OF NTRK GENE FUSION-POSITIVE LUNG CANCER - WORLDWIDE
  • FIGURE 13: PREVALENCE OF NTRK GENE FUSION-POSITIVE BREAST CANCER - WORLDWIDE
  • FIGURE 14:PREVALENCE RATE PER 100000 OF NTRK GENE FUSION-POSITIVE BREAST CANCER - WORLDWIDE
  • FIGURE 15: PREVALENCE OF NTRK GENE FUSION-POSITIVE SBC - WORLDWIDE
  • FIGURE 16: PREVALENCE RATE PER 100000 OF NTRK GENE FUSION-POSITIVE SBC - WORLDWIDE
  • FIGURE 17: PREVALENCE OF NTRK GENE FUSION-POSITIVE COLORECTAL CANCER - WORLDWIDE
  • FIGURE 18: PREVALENCE OF NTRK GENE FUSION-POSITIVE COLORECTAL CANCER - US AND EUROPE
  • FIGURE 19: COMPARISON OF PREVALENCE POPULATION OF OTHER CANCERS WITH NTRK GENE FUSIONS - WORLWIDE
  • FIGURE 20: SHARE OF PREVALENCE OF OTHER CANCERS WITH NTRK GENE FUSIONS - US